Development of a Predictive Score for the Risk of Infection in the Immediate Post-liver-transplant Period

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with severe liver disease who are waiting for a liver transplant and then receive it. Blood samples are taken to help predict infection risk soon after the transplant.

Életkor

18 years and older

Nem

All sexes

A betegség stádiuma

Waiting for a liver transplant because of one of these: compensated cirrhosis (liver scarring) with hepatocellular carcinoma (liver cancer); chronically decompensated cirrhosis (for example repeated gut bleeding, fluid in the belly that does not respond to treatment, brain problems from liver disease, chronic liver failure); acute decompensated cirrhosis, with or without failure of other organs (ACLF); or acute fulminant hepatitis (sudden severe liver failure). People must receive the transplant and give a blood sample on the day of the transplant.

Korábbi kezelés

People cannot have had immunosuppressive therapy (medicine that weakens the immune system) before the transplant. Corticosteroids at 40 mg per day for alcoholic hepatitis are allowed. No other immune-changing therapy, such as immune checkpoint inhibitors, before the transplant.

A részvétel fő kizáró okai

• People under 18
• Pregnant or breastfeeding women
• Waiting for a transplant of more than one organ at once
• Under legal guardianship or conservatorship, or deprived of liberty
• Not enrolled in the social security system

Ez a vizsgálat csak szervátültetésen átesett résztvevőket keres. A regiszter mondata, amelyen ez alapul: Patients receiving LT AND

A regiszter feltételei, szó szerint

Mit akar kideríteni a vizsgálat

Liver transplantation (LT) is the only curative treatment option for patients with severe liver disease. Since 2007, the implementation of the MELD score in liver transplant allocation guidelines has led to a change in the profile of transplant recipients, notably with an increase in the proportion of patients receiving transplants for severe liver failure. Thus, in 2023, nearly 40% of liver transplant recipients whose primary indication for LT was cirrhosis had a MELD score greater than 35 (ABM Scientific Report 2023). These patients with severe pre-transplant liver failure often present with associated organ failure (Acute-on-Chronic Liver Failure, ACLF). Infections are the leading cause of death at 1 year post-transplant for patients transplanted with ACLF and are a major concern for all patients, representing one of the leading causes of death at 3 months post-transplant. Another common complication following LT is acute cellular rejection. Although frequent, this complication is reversible with treatment and results in graft loss in fewer than 5% of cases.

A vizsgálat csoportja

• Patients with severe liver disease waiting for liver transplantation (LT)

  Only patients with the most frequent Liver transplantation (LT) indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral and fulminant hepatitis

  Kezelés: blood sampling és Biocollection